You are here
- Home
- Therapy Areas
- Respiratory/Inflammation
A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)
- Disease
- autoimmune diseases
- Generic Name
- MEDI-546
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- II
- Start Date
- Apr 20, 2012
- Study Name
- D3461C00002
- Study Id
- D3461C00002
- ClinicalTrials.gov ID
- NCT01559090
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
